IHAM
TVTX icon

Integral Health Asset Management’s Travere Therapeutics TVTX Stock Holding History

Integral Health Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.3M Buy
+375,000
New +$16.6M 0.84% 33
2025
Q1 		– Sell
-100,000
Closed -$1.74M – 108
2024
Q4 		$1.74M Buy
+100,000
New +$1.77M 0.15% 76
2021
Q2 		– Sell
-15,000
Closed -$375K – 89
2021
Q1 		$375K Buy
+15,000
New +$414K 0.11% 68

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Integral Health Asset Management's TVTX Position: Q2 2026 in Review

Integral Health Asset Management opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 375,000 shares worth $21.3M. The stake represents 0.84% of the portfolio and ranks #33 among its holdings. This is a return to the name: Integral Health Asset Management previously reported a position in TVTX as recently as Q4 2024.

Integral Health Asset Management first reported a position in TVTX in Q1 2021 and has held it in 3 quarters since. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Integral Health Asset Management held 375,000 shares of Travere Therapeutics worth $21.3M as of Q2 2026.
  • Travere Therapeutics was a new Integral Health Asset Management position in Q2 2026.
  • Travere Therapeutics made up 0.84% of Integral Health Asset Management's portfolio in Q2 2026, its #33 holding.
  • Integral Health Asset Management first reported a position in Travere Therapeutics in Q1 2021 and has held it in 3 quarters since.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Integral Health Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.